| Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5) (NCT03964012) | Serum Institute of India Pvt. Ltd. | 2019-08-20 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers (NCT02955797) | Sanofi Pasteur, a Sanofi Company | 2017-02-24 |
| Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years (NCT03077438) | Sanofi Pasteur, a Sanofi Company | 2017-02-17 |
| Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age (NCT02919293) | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 2016-08-01 |
| Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea (NCT02864927) | Sanofi Pasteur, a Sanofi Company | 2016-07-21 |
| Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine (NCT02842853) | Sanofi Pasteur, a Sanofi Company | 2016-07-15 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older (NCT02842866) | Sanofi Pasteur, a Sanofi Company | 2016-07-15 |
| Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam (NCT02640404) | Sanofi Pasteur, a Sanofi Company | 2016-06-06 |
| Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine (NCT02752906) | Sanofi Pasteur, a Sanofi Company | 2016-04-15 |
| Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation (NCT02699840) | Sanofi Pasteur, a Sanofi Company | 2016-02-01 |
| Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier (NCT02633787) | Sanofi Pasteur, a Sanofi Company | 2015-12-01 |
| Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects (NCT02591290) | Sanofi Pasteur, a Sanofi Company | 2015-10-20 |
| A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine (NCT02481232) | Lanzhou Institute of Biological Products Co., Ltd | 2015-06-01 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers (NCT03205358) | Sanofi Pasteur, a Sanofi Company | 2015-03-31 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents (NCT02199691) | Sanofi Pasteur, a Sanofi Company | 2014-07-22 |
| Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NCT01897402) | JN-International Medical Corporation | 2013-07-01 |
| Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 (NCT01894919) | Novartis Vaccines | 2013-06-01 |
| A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults (NCT01478347) | Novartis Vaccines | 2013-05-01 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older (NCT01732627) | Sanofi Pasteur, a Sanofi Company | 2012-11-12 |
| Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 (NCT01717638) | Novartis Vaccines | 2012-11-01 |
| Comparison of Two Meningococcal ACWY Conjugate Vaccines (NCT01192997) | Public Health England | 2012-06-01 |
| Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects (NCT01519713) | Sanofi Pasteur, a Sanofi Company | 2012-01-01 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults (NCT01466387) | Novartis | 2011-11-01 |
| Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis (NCT01482052) | JN-International Medical Corporation | 2011-11-01 |
| Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine (NCT01453348) | Novartis Vaccines | 2011-10-01 |
| A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents (NCT01424644) | Novartis | 2011-09-01 |
| Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers (NCT01434680) | Novartis | 2011-09-01 |
| Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years (NCT01423084) | Novartis | 2011-08-01 |
| Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines (NCT01367158) | Novartis Vaccines | 2011-07-01 |
| A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years (NCT01339923) | Novartis Vaccines | 2011-04-01 |
| A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea (NCT01274897) | Novartis Vaccines | 2010-12-01 |
| Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination (NCT01239043) | Sanofi | 2010-11-01 |
| Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life (NCT01214837) | Novartis Vaccines | 2010-10-01 |
| Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 (NCT01148524) | Novartis Vaccines | 2010-08-01 |
| Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine (NCT01148017) | Novartis Vaccines | 2010-07-01 |
| Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 (NCT00944034) | Novartis Vaccines | 2009-07-01 |
| Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine (NCT00856297) | Novartis Vaccines | 2009-02-01 |
| Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers (NCT00667602) | Novartis Vaccines | 2008-03-01 |
| Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years (NCT00874549) | Sanofi Pasteur, a Sanofi Company | 2007-10-01 |
| A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents (NCT00518180) | Novartis Vaccines | 2007-07-01 |
| Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers (NCT00483574) | Sanofi Pasteur, a Sanofi Company | 2007-05-01 |
| A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults (NCT00474487) | Novartis Vaccines | 2007-05-01 |
| A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults (NCT00450437) | Novartis Vaccines | 2007-03-01 |
| Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers (NCT00422292) | Sanofi Pasteur, a Sanofi Company | 2006-12-01 |
| Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® (NCT00355121) | Sanofi | 2006-10-01 |
| A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers (NCT00384397) | Sanofi Pasteur, a Sanofi Company | 2006-09-01 |
| Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years (NCT00329901) | Novartis Vaccines | 2006-04-01 |
| Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine (NCT00994695) | Armauer Hansen Research Institute, Ethiopia | 2005-11-01 |
| Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months) (NCT00310856) | Novartis Vaccines | 2005-06-01 |
| Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. (NCT00310817) | Novartis Vaccines | 2005-03-01 |